Therefore, the above results implicate that pharmacological inhibition of S100A9 using Paquinimod can ameliorate immune dissonance caused by sustainable septic exposure, suggesting the therapeutic potential of targeting S100Ahigh monocytes for the management of sepsis-induced immunosuppression. This evidence concerns the gene S100A9 and Sepsis.